Suppr超能文献

表观遗传学失活的假定肿瘤抑制因子 SFRP3 与肺腺癌患者的不良预后相关。

Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients.

机构信息

a Institute of Pathology , Medical Faculty of the RWTH Aachen University , Aachen , Germany.

b Institute of Complex Systems, Research Center Jülich , Jülich , Germany.

出版信息

Epigenetics. 2018;13(3):214-227. doi: 10.1080/15592294.2016.1229730. Epub 2018 Apr 18.

Abstract

Secreted frizzled related protein 3 (SFRP3) contains a cysteine-rich domain (CRD) that shares homology with Frizzled CRD and regulates WNT signaling. Independent studies showed epigenetic silencing of SFRP3 in melanoma and hepatocellular carcinoma. Moreover, a tumor suppressive function of SFRP3 was shown in androgen-independent prostate and gastric cancer cells. The current study is the first to investigate SFRP3 expression and its potential clinical impact on non-small cell lung carcinoma (NSCLC). WNT signaling components present on NSCLC subtypes were preliminary elucidated by expression data of The Cancer Genome Atlas (TCGA). We identified a distinct expression signature of relevant WNT signaling components that differ between adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC). Of interest, canonical WNT signaling is predominant in LUAD samples and non-canonical WNT signaling is predominant in LUSC. In line, high SFRP3 expression resulted in beneficial clinical outcome for LUAD but not for LUSC patients. Furthermore, SFRP3 mRNA expression was significantly decreased in NSCLC tissue compared to normal lung samples. TCGA data verified the reduction of SFRP3 in LUAD and LUSC patients. Moreover, DNA hypermethylation of SFRP3 was evaluated in the TCGA methylation dataset resulting in epigenetic inactivation of SFRP3 expression in LUAD, but not in LUSC, and was validated by pyrosequencing of our NSCLC tissue cohort and in vitro demethylation experiments. Immunohistochemistry confirmed SFRP3 protein downregulation in primary NSCLC and indicated abundant expression in normal lung tissue. Two adenocarcinoma gain-of-function models were used to analyze the functional impact of SFRP3 on cell proliferation and regulation of CyclinD1 expression in vitro. Our results indicate that SFRP3 acts as a novel putative tumor suppressor gene in adenocarcinoma of the lung possibly regulating canonical WNT signaling.

摘要

分泌卷曲相关蛋白 3(SFRP3)含有一个富含半胱氨酸的结构域(CRD),与卷曲 CRD 具有同源性,并调节 WNT 信号通路。独立的研究表明,黑色素瘤和肝细胞癌中 SFRP3 的表观遗传沉默。此外,SFRP3 在雄激素非依赖性前列腺癌和胃癌细胞中具有肿瘤抑制作用。目前的研究首次调查了 SFRP3 在非小细胞肺癌(NSCLC)中的表达及其潜在的临床影响。通过癌症基因组图谱(TCGA)的表达数据初步阐明了 NSCLC 亚型中的 WNT 信号成分。我们确定了一个不同的相关 WNT 信号成分的表达特征,这些成分在腺癌(LUAD)和鳞状细胞癌(LUSC)之间存在差异。有趣的是,经典的 WNT 信号在 LUAD 样本中占主导地位,而非经典的 WNT 信号在 LUSC 中占主导地位。同样,SFRP3 的高表达导致 LUAD 患者而不是 LUSC 患者的临床获益。此外,与正常肺组织样本相比,NSCLC 组织中 SFRP3 的 mRNA 表达显著降低。TCGA 数据证实了 LUAD 和 LUSC 患者中 SFRP3 的减少。此外,在 TCGA 甲基化数据集中评估了 SFRP3 的 DNA 超甲基化,导致 LUAD 中 SFRP3 表达的表观遗传失活,但在 LUSC 中没有,并且通过我们的 NSCLC 组织队列的焦磷酸测序和体外去甲基化实验得到了验证。免疫组化证实了原发性 NSCLC 中 SFRP3 蛋白的下调,并表明正常肺组织中大量表达。使用两个腺癌获得功能模型来分析 SFRP3 对细胞增殖的功能影响,并体外调节 CyclinD1 的表达。我们的结果表明,SFRP3 可能通过调节经典的 WNT 信号通路,作为一种新的潜在的肿瘤抑制基因在肺腺癌中发挥作用。

相似文献

引用本文的文献

6
Wnt antagonist as therapeutic targets in ovarian cancer.Wnt拮抗剂作为卵巢癌的治疗靶点。
Int J Biochem Cell Biol. 2022 Apr;145:106191. doi: 10.1016/j.biocel.2022.106191. Epub 2022 Mar 7.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验